What are the advantages and disadvantages of atomoxetine (Strattera) compared with ONYDA (extended‑release clonidine) and guanfacine (extended‑release guanfacine, Intuniv) for treating ADHD?

Atomoxetine vs. ONYDA (Clonidine ER) vs. Guanfacine ER for ADHD

Atomoxetine is generally the preferred non-stimulant for ADHD when efficacy is the primary concern, offering superior symptom control compared to alpha-2 agonists, though guanfacine ER may be chosen when sedation is desired or when treating comorbid aggression, tics, or sleep disturbances. 1

Comparative Efficacy

All three medications are FDA-approved non-stimulants with medium effect sizes that are smaller than stimulants 1. However, their relative efficacy differs:

• Atomoxetine shows superior efficacy to guanfacine in head-to-head comparisons using matching-adjusted indirect comparison methodology, with significantly greater reductions in ADHD-RS-IV total scores (-7.0 points, p<0.01) 2
• Guanfacine ER appears superior to atomoxetine according to one 2015 review, though this conflicts with the more rigorous 2013 analysis 3, 2
• Clonidine and guanfacine have similar efficacy to each other, though long-term maintenance data is better established for atomoxetine and guanfacine than clonidine 1

The 2022 Pharmacology & Therapeutics guidelines note that atomoxetine and guanfacine both improve functional impairment and quality of life beyond core ADHD symptoms 1.

Onset of Action

This is a critical practical difference:

• Atomoxetine: 6-12 weeks for full therapeutic effect 1
• Clonidine ER: 2-4 weeks 1
• Guanfacine ER: 2-4 weeks 1

Alpha-2 agonists provide faster symptom relief, which may be important when rapid intervention is needed.

Dosing & Administration

Atomoxetine (Strattera)

• Target dose: 1.2 mg/kg/day (max 1.4 mg/kg or 100 mg, whichever is less) 4
• Can be given once daily or split into two doses (morning and evening) 1
• Can be administered in evening only if needed 1
• Requires dose adjustment in hepatic impairment (50% reduction for moderate, 75% reduction for severe) 4
• Requires dose adjustment with CYP2D6 inhibitors or in poor metabolizers 4

Clonidine ER (ONYDA)

• Starting dose: 0.1 mg at bedtime, titrate to max 0.4 mg/day 1
• Evening administration preferred due to sedation 1
• Metabolized via CYP2D6 1
• Available as transdermal patch (0.1,0.2,0.3 mg) 1

Guanfacine ER (Intuniv)

• Weight-based dosing: ~0.1 mg/kg once daily (1-4 mg tablets) 1
• Evening administration preferred due to sedation 1
• Metabolized via CYP3A4 1
• 10 times less potent than clonidine but more alpha-2A receptor specific 1

Adverse Effect Profiles

Atomoxetine

Most common: Nausea, vomiting, fatigue, decreased appetite, abdominal pain, somnolence 1

Advantages:

• Less sedation than alpha-2 agonists 1
• Fewer growth/height problems compared to stimulants 1
• Similar cardiovascular effects to stimulants (minimal) 1
• No abuse potential (not a controlled substance) 1

Critical warnings:

• Black box warning for suicidal ideation in children/adolescents (4 per 1000 patients) 1, 4
• Severe liver injury (rare but serious) 4
• Monitor for cardiovascular effects, psychotic/manic symptoms 1, 4
• 7% of population are poor metabolizers with higher plasma levels and increased side effects 1

Clonidine ER & Guanfacine ER

Most common (both): Somnolence, fatigue, irritability, insomnia, nightmares 1

Clonidine-specific: Dry mouth, sedation, bradycardia, syncope (more pronounced than guanfacine) 1

Critical warnings (both):

• Hypotension/bradycardia 1
• Cardiac conduction abnormalities 1
• Rebound hypertension with abrupt discontinuation 1
• No abuse potential (not controlled substances) 1

Guanfacine has less sedation than clonidine due to higher alpha-2A receptor specificity 1

Clinical Decision Algorithm

Choose Atomoxetine When:

• Efficacy is the primary concern and patient can wait 6-12 weeks 1, 2
• Sedation is undesirable 1
• Patient has substance use disorder (no abuse potential) 1
• Around-the-clock coverage is needed 1
• Patient can tolerate GI side effects 1

Choose Guanfacine ER When:

• Faster onset needed (2-4 weeks vs 6-12 weeks) 1
• Comorbid aggression, conduct disorder, or oppositional defiant disorder 1
• Comorbid tic disorder or Tourette's syndrome 1
• Sleep disturbances present (sedation is beneficial) 1
• Anxiety or PTSD symptoms present 5, 6
• Patient has hepatic impairment (atomoxetine requires dose reduction) 4
• Less sedation desired compared to clonidine 1

Choose Clonidine ER (ONYDA) When:

• Same indications as guanfacine but more sedation is acceptable or desired 1
• Transdermal delivery is preferred (patch available) 1
• Patient is on medications metabolized by CYP3A4 (clonidine uses CYP2D6) 1

Avoid Atomoxetine When:

• Hepatic impairment (requires significant dose reduction) 4
• History of suicidal ideation (black box warning) 1, 4
• Patient cannot tolerate 6-12 week wait for efficacy 1
• Taking MAOIs (contraindicated) 4

Avoid Alpha-2 Agonists When:

• Cardiac conduction abnormalities present 1
• Significant hypotension or bradycardia 1
• Patient cannot tolerate sedation/fatigue 1
• Abrupt discontinuation likely (rebound hypertension risk) 1

Special Populations

Comorbid Autism Spectrum Disorder: Atomoxetine shows modest effects on hyperactivity and inattention with relatively benign side effect profile; methylphenidate more effective but higher dropout rates 7

Trauma/PTSD: Alpha-2 agonists (guanfacine, clonidine) show most consistent improvement in trauma-related symptoms 6

Substance Use Disorder: Non-stimulants preferred; atomoxetine and alpha-2 agonists both viable as they lack abuse potential 1

Adjunctive Therapy

All three medications are FDA-approved as adjunctive therapy to stimulants in the US 1. Alpha-2 agonists may specifically reduce stimulant-induced sleep disturbances and cardiovascular effects 1.

Key Pitfalls

• Don't expect rapid results with atomoxetine - counsel patients about 6-12 week timeline 1
• Don't abruptly discontinue alpha-2 agonists - taper to avoid rebound hypertension 1
• Don't open atomoxetine capsules - must be swallowed whole 4
• Don't forget dose adjustments for atomoxetine in hepatic impairment or with CYP2D6 inhibitors 4
• Monitor cardiovascular parameters with all three medications 1, 4
• Screen for suicidal ideation when initiating atomoxetine, especially in first few months 1, 4